Ascendis Pharma A (ASND) Depreciation and Depletion (2017 - 2025)

Ascendis Pharma A (ASND) has 9 years of Depreciation and Depletion data on file, last reported at $5.5 million in Q4 2025.

• For the quarter ending Q4 2025, Depreciation and Depletion rose 17.41% year-over-year to $5.5 million; the trailing twelve-month figure through Dec 2025 stood at $19.4 million (up 4.01% YoY), and the FY2025 full-year result was $20.0 million, up 7.29% from the prior year.
• Depreciation and Depletion improved to $5.5 million in Q4 2025, from $4.6 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $5.5 million in Q4 2025 to a low of $4.2 million in Q2 2021.
• A 5-year average of $4.7 million and a median of $4.7 million in 2024 frame the typical range for Depreciation and Depletion.
• Across the five-year window, Depreciation and Depletion surged 97.54% in 2021 and declined 10.37% in 2024, its largest moves.
• Tracing ASND's Depreciation and Depletion over 5 years: stood at $4.8 million in 2021, then retreated by 3.02% to $4.6 million in 2022, then grew by 12.47% to $5.2 million in 2023, then retreated by 10.37% to $4.7 million in 2024, then gained by 17.41% to $5.5 million in 2025.
• Business Quant data shows ASND's Depreciation and Depletion at $5.5 million in Q4 2025, $4.6 million in Q3 2025, and $4.7 million in Q2 2025.